MedWatch

ALK execs rake in profits after exercising share options

Several of the top leaders at ALK utilized their share options at the start of this week, gaining shares in the firm that they have since sold for million-kroner profits.

ALK CEO Carsten Hellmann | Photo: Gregers Tycho/ERH

At the start of this week, several of the top managers at allergy firm ALK exercised their rights to buy shares in the company. They have since sold these shares again, resulting in substantial profits, an internal memo reveals.

CEO Carsten Hellmann made two transactions. One of those involved exercising his options and purchasing 86,692 shares at DKK 41.12 (USD 5.8) per share, spending a total of DKK 3,564,775 (USD 503,221).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs